Please assess the completion status of the following clinical trial:

Trial Title: CC-5013 (Lenalidomide) and Rituximab in Waldenstrom's Macroglobulinemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinicopathological diagnosis of Waldenstrom's macroglobulinemia using consensus panel criteria~* Age 18 years or older~* CD20 positive based on any previous bone marrow immunohistochemistry or flow cytometric analysis~* All previous cancer therapy, including radiation, hormonal therapy and surgery, must have been discontinued at least 4 weeks prior to treatment in this study~* Measurable disease, defined as presence of immunoglobulin M paraprotein with a minimum IgM level of equal to or greater than 2 times the upper limit of normal.~* ECOG performance status of 0-2~* Absolute neutrophil count ≥ 100,000,000/L~* Platelet count ≥ 50,000,000,000/L~* Hemoglobin \> 8 g/dL~* Serum creatinine \< 2.5 mg/dL~* Total bilirubin \< 1.5 mg/dL~* AST and ALT \< 2.5 x ULN~* Disease free of prior malignancies fir 5 years with exception of currently treated basal cell, squamous cell carcinoma of the skin, or carcinoma in situ of the cervix or breast~Exclusion Criteria:~* Any serious medical condition, laboratory abnormality, or psychiatric illness~* Pregnant or lactating women~* Prior therapy with rituximab or CC-5103~* Known hypersensitivity to thalidomide~* Development of erythema nodosum if characterized by a desquamating rash while taking thalidomide or similar drugs.~* Concurrent use of other anti-cancer agents or treatments

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- CC-5103 (Lenalidomide) and Rituximab (Type: EXPERIMENTAL): Intended therapy consisted of 48 weeks of CC-5103 (lenalidomide)(25 mg/d for 3 weeks and then 1 week off) along with rituximab (375 mg/m(2)/wk) dosed on weeks 2 to 5 and 13 to 16.

Based on this trial design, predict the completion outcome and termination type (if applicable).